Publications by authors named "A Bramati"

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective in non- small cell lung cancer (NSCLC) with EGFR mutations. Since the drug is primally eliminated by the fecal route no dose adjustment is needed in patient with chronic-kidney disease (CKD); despite this there is limited data about its safety in cancer patients with end-stage renal disease (ESRD). Herein, we reported a case report of a 77-year-old woman, diagnosed in 2018 with lung adenocarcinoma EGFR mutated with lymph nodal and cerebral metastasis, who started Osimertinib 80 mg/day.

View Article and Find Full Text PDF

Achieving pure single-photon emission is essential for a range of quantum technologies, from quantum computing to quantum key distribution to quantum metrology. Among solid-state quantum emitters, colloidal lead halide perovskite (LHP) nanocrystals (NCs) have attracted considerable interest due to their structural and optical properties, which make them attractive candidates for single-photon sources (SPSs). However, their practical utilization has been hampered by environment-induced instabilities.

View Article and Find Full Text PDF

Vacuum quantum fluctuations near horizons are known to yield correlated emission by the Hawking effect. We use a driven-dissipative quantum fluid of microcavity polaritons as an analog model of a quantum field theory on a black-hole spacetime and numerically calculate correlated emission. We show that, in addition to the Hawking effect at the sonic horizon, quantum fluctuations may result in a sizable stationary excitation of a quasinormal mode of the field theory.

View Article and Find Full Text PDF
Article Synopsis
  • Metastatic breast cancer (MBC) is an incurable disease, and treatment with eribulin aims to extend overall survival and improve patients' quality of life, but it can cause significant side effects like fatigue and neurological issues.
  • The PAINTER study evaluated the tolerability, efficacy, and safety of eribulin among 180 patients across 20 Italian centers, with a median follow-up of 15.4 months, revealing a median overall survival of 12 months and substantial adverse events.
  • Genetic analysis identified a connection between specific genetic variations (SNPs) and the occurrence of peripheral neuropathy, suggesting that genetic factors may impact the severity of side effects in patients treated with eribulin
View Article and Find Full Text PDF

Characterizing elementary excitations in quantum fluids is essential to study their collective effects. We present an original angle-resolved coherent probe spectroscopy technique to study the dispersion of these excitation modes in a fluid of polaritons under resonant pumping. Thanks to the unprecedented spectral and spatial resolution, we observe directly the low-energy phononic behavior and detect the negative-energy modes, i.

View Article and Find Full Text PDF